CN-121975675-A - Bacillus coagulans and application thereof in degrading alcohol and relieving alcoholic liver injury

Abstract

The invention belongs to the technical field of microorganisms, in particular to bacillus coagulans and application thereof in degrading alcohol and relieving alcoholic liver injury, the strain has excellent ethanol degradation capability and probiotics characteristics, can effectively inhibit pathogenic bacteria, and has good safety. Animal experiments prove that the composition can effectively relieve intestinal barrier dysfunction, liver inflammation, oxidative stress, lipid metabolism disorder and intestinal flora disorder caused by alcohol induction. The bacillus coagulans can be applied to preparation of medicines, foods, food additives, feeds and feed additives for relieving alcoholic liver injury.

Inventors

• LU YINGJIAN
• YANG FEIYU
• LI XIANGFEI
• PANG XINYI
• SUN JING
• CHEN CHI

Assignees

• 南京财经大学

Dates

Publication Date

20260505

Application Date

20251229

Claims (10)

1. 1. A strain of Bacillus coagulans, designated Heyndrickxia coagulans, is deposited with the Guangdong province microorganism strain collection under the accession number GDMCCNo.67374.
2. 2. The bacillus coagulans according to claim 1, wherein the bacillus coagulans is isolated from reed chicken manure.
3. 3. A microbial preparation comprising one or more of a fermentation broth, a fermentation broth precipitate, a fermentation broth supernatant, a live bacterium, a dead bacterium, a spore, an active ingredient or a lyophilized powder containing a bacterium, which is produced by the Bacillus coagulans of claim 1 or 2.
4. 4. Use of the bacillus coagulans of claim 1 or 2 for the preparation of a feed or feed additive.
5. 5. Use of the bacillus coagulans of claim 1 or 2 for the preparation of a food or food additive.
6. 6. Use of the bacillus coagulans according to claim 1 or 2 for preparing a food fresh-keeping packaging material.
7. 7. Use of the bacillus coagulans of claim 1 or 2 for the preparation of a medicament for preventing, alleviating or treating an alcoholic disease.
8. 8. The use according to claim 7, further comprising other drugs compatible with the bacillus coagulans and pharmaceutically acceptable carriers and/or adjuvants.
9. 9. The use according to claim 7, wherein the pharmaceutical dosage form comprises one or more of powder, granule, capsule, tablet, oral liquid, syrup, pill, nano-preparation or injection.
10. 10. The use according to claim 7, wherein the disease comprises alcoholic liver injury or digestive tract injury.

Description

Bacillus coagulans and application thereof in degrading alcohol and relieving alcoholic liver injury Technical Field The invention belongs to the technical field of microorganisms, and particularly relates to bacillus coagulans for screening stool from Luhua chickens and application of bacillus coagulans in degrading alcohol and relieving alcoholic liver injury. Background Alcohol, a psychoactive and toxic substance, has been shown to lead to the progression of a variety of diseases, being a major risk factor for the global disease burden. The liver is used as a main organ of alcohol metabolism, and is directly and toxicity acted by ethanol and acetaldehyde which is a metabolite of the ethanol, so that continuous damage of liver cells is caused. Thus, alcoholic liver disease is one of the most common causes of liver-related morbidity and mortality. The disease spectrum of alcoholic liver disease includes alcoholic fatty liver, alcoholic hepatitis, fibrosis, cirrhosis, and even liver cancer. The progression is affected by complex interactions of many factors, such as alcohol abuse duration, drinking pattern, genetic polymorphisms, sex and metabolic profile. The pathogenesis of alcoholic liver disease is multifaceted, involving multiple interrelated mechanisms of alcohol metabolism initiation. Byproducts produced by ethanol during the metabolic process induce liver lipid accumulation, oxidative stress, endoplasmic reticulum stress and apoptosis. In addition, long-term ethanol consumption can also cause intestinal dysbiosis, destroy tight junction proteins among intestinal epithelial cells, and increase intestinal permeability. Eventually leading to translocation of bacterial products such as endotoxins to the liver through the intestinal liver shaft, causing inflammation and "secondary hits" to the liver. Currently, most modern commercial anti-alcohol and anti-alcohol products do not directly degrade accumulated alcohol in the body, but rather accelerate the metabolic processes of alcohol in the body by promoting the activity of Alcohol Dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH) in the liver of the human body. However, the regulation of the activity of these enzymes by the human body is a complex physiological process, and simply relying on external drugs to increase the enzyme activity may not be stable, and the individual differences are large. Some sober-up products attempt to reduce alcohol absorption by forming a protective film in the gastrointestinal tract or combining with alcohol. However, this method can only delay the speed of alcohol entering the blood to some extent, and cannot completely prevent alcohol absorption. Moreover, once the protective film is broken or the bonding effect is saturated, alcohol is still absorbed by the human body. Furthermore, some anti-hangover drugs lack independent scientific evidence about their efficacy and safety, and even have potential side effects. Therefore, it is important to find a therapeutic approach that can effectively degrade ethanol and can alleviate the progression of Alcoholic Liver Disease (ALD). Probiotics, by virtue of their diverse functional properties and excellent health potential, play a vital role in the medical health field, and have been applied to a variety of animal models and human clinical studies. Researches prove that probiotics can improve alcoholic liver injury by regulating intestinal microbiota, enhancing intestinal mucosa immune function of a host, inhibiting various bacterial pathogens, promoting liver enzyme activity of the host and other functions. Bacillus coagulans is a gram-positive, facultative anaerobic, endospore-forming and lactic acid-producing bacterium. Due to the spore-producing property, bacillus coagulans shows extremely strong tolerance to severe environments such as high temperature, acidic conditions, bile salts and the like. This enables it to survive in harsh environments where normal probiotics cannot survive, and then germinate and reproduce when the environment is appropriate. In the medical field, this feature provides a significant advantage over other probiotics. As a new strain, bacillus coagulans has been increasingly used in the field of human health. Disclosure of Invention In order to solve the problems that ethanol is difficult to effectively degrade and the progress of alcoholic liver diseases is relieved in the prior art, the invention mainly provides bacillus coagulans (Heyndrickxia coagulans) JF1 which can efficiently degrade ethanol and relieve alcoholic liver injury, and the technical scheme is as follows: bacillus coagulans designated Heyndrickxia coagulans, deposited at the Guangdong province microorganism strain collection under the accession number GDMCC No.67374. The preservation date is 2025, 11 and 27; The preservation unit is the microorganism strain preservation center in Guangdong province; The preservation unit is GDMCC; the preservation address is building 5 of Gua